-
Aussie Rules fires appeals chair over ruling on anti-gay slur
-
Lakers' OT win puts Rockets on brink of NBA playoff elimination
-
From radiation to invasion: a Chernobyl worker's two wars
-
AI firms flex lobbying muscle on both side of Atlantic
-
First female Archbishop of Canterbury to meet Pope Leo
-
Hundreds of firefighters battle Japan forest blazes
-
Lakers down Rockets in overtime for 3-0 series lead, Celtics hold off Sixers
-
US envoys heading to Pakistan for uncertain Iran talks
-
'Hockey is religion': Montreal fans pack church for playoff push
-
Billionaire Elon Musk enters courtroom showdown with OpenAI
-
Crunch nuclear proliferation meeting at UN amid raging global wars
-
Awkward debut for Trump at correspondents' dinner
-
Under blackout threat, Wikimedia reaches compromise with Indonesia
-
'Going to the moon': Irish footballers return to China 50 years after historic tour
-
Spurs' Wembanyama ruled out of game 3 after concussion
-
Palestinians to vote in first elections since Gaza war
-
Pragmatism, not patriotism, pushes young Lithuanians to military service
-
Peru confirms election runoff date, court says no to Lima re-vote
-
Venezuela, Colombia pledge military cooperation on first post-Maduro visit
-
US hopes for progress, but Iran says not direct talks
-
Maine governor nixes data center moratorium in state
-
Betis's Bellerin further dents Real Madrid title hopes
-
Lens rally but title bid fades after draw at Brest
-
OpenAI CEO apologizes to Canada town for not reporting mass shooter
-
UK PM vows legislation to ban Iran Guards: report
-
Leipzig tighten top-four grip as Union's Eta suffers second loss
-
Furyk named USA captain for 2027 Ryder Cup
-
EU, US sign critical minerals plan to counter China reliance
-
The 'housewives' did well -- Ukraine takes drone know-how abroad
-
Court removes US businessman from managing his Brazilian football team
-
'Natural' birth control risks unwanted pregnancy, experts warn
-
No.2 Korda boosts LPGA Chevron lead to seven
-
EU trade chief seeks 'positive traction' on US steel tariffs
-
Anthropic says Google to pump $40 bn into AI startup
-
Kohli makes Gujarat pay as Bengaluru cruise to IPL win
-
One injured in bomb attack on Colombia military base
-
Envoys from Iran, US expected in Pakistan for new talks
-
ILO names US official as number two amid grumbling over unpaid dues
-
Son of director Rob Reiner pays tribute to slain parents
-
AI united Altman and Musk, then drove them apart
-
Sinner overcomes Bonzi in record hunt at Madrid Open
-
Havana property market stirs as investors bet on political change
-
Children's lives at risk from US funding cuts to vaccine alliance: CEO
-
Brazil's Lula has surgery to remove skin lesion from scalp
-
Defending champion Alcaraz to miss French Open with wrist injury
-
Battle lines drawn over EU's next big budget
-
Renewed hopes of Iran peace talks keep oil under $100 per barrel
-
Lebanon truce extended as Pakistan bids to revive US-Iran talks
-
Assisted dying bill scuppered as UK advocates vow to fight on
-
Alex Marquez quickest in Spanish MotoGP practice
Brazilian ritual root gets second life as potential anti-depressant
Long used in Indigenous Brazilian rituals, the jurema preta plant, which contains a potent psychedelic, is gaining ground as a potential treatment for depression.
At street stalls where medicinal herbs are sold, customers can buy the plant's root which contains dimethyltryptamine (DMT), a hallucinogenic substance that researchers say could be used to alleviate symptoms.
Following instructions he found on the internet, Guaracy Carvajal extracted DMT at home in 2016 from roots he bought on the street.
The 31-year-old software programmer, who had tried various treatment for chronic depression he has suffered since adolescence, said the drug makes it "feel like you've solved something in your life."
Physicist Draulio Araujo, who has conducted extensive research on the drug, said "the response is rapid. One day after treatment, (patients) already showed a significant improvement in their depression symptoms."
Yet he also warned that it "is not a magic cure" and that psychedelics "are not for everyone."
As a researcher at the Brain Institute of the Federal University of Rio Grande do Norte, Araujo and his team treated 14 people with the drug for six months.
The patients inhaled vaporized DMT, under medical supervision.
"It's common for our patients to say that something changed, that a key opened something," he said.
His patients also received psychological therapy, and some continued with conventional pharmaceutical drugs.
Neuroscientist Fernanda Palhano-Fontes, also of the Brain Institute, said "we have patients who improve significantly, others who don't improve at all."
Araujo's findings were published in the scientific journal Nature in April. In 2024, he published another study with promising results in the journal Psychedelic Medicine.
As for Carvajal, who stopped using jurema preta some time ago, he said the drug really allows a person to "start to have a lighter life."
It helped him get through a time when he was in "a state of questioning myself" about "work, day-to-day life," he said.
- Spiritual channels -
Brazil occupies a fairly prominent place in DMT research due to the substance's prominence in society, Araujo said.
While there is no ban on the cultivation or possession of jurema, which is also known as Mimosa tenuiflora, consumption of DMT is prohibited, except for religious and scientific use.
Jurema's roots are combined with other plants in a wine-like beverage that is consumed at rituals that include dancing and drums, part of Indigenous tradition in northeast Brazil where the plant grows.
"It's not hallucination," said Joyce Souza, a young woman attending a jurema ceremony in Planaltina, on the outskirts of Brasília.
"My spiritual channels become more accessible, I can communicate better with myself," Souza said.
Gathered in a house courtyard and dressed in white, the group of mostly novices waited for more seasoned practitioners to enter a trance and bring messages from ancient spirits.
Meanwhile, back in the lab, Araujo is hoping to expand his DMT research to a study of 100 patents.
"Let's say that in five years we'll have... a clear picture on when it will reach a real clinical setting," he said.
A.Malone--AMWN